Please ensure Javascript is enabled for purposes of website accessibility

Roche's Rheumatoid Arthritis Drug Actemra Fails to Help COVID-19 Patients With Pneumonia

By Brian Orelli, PhD – Jun 18, 2020 at 7:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There are still two ongoing studies of the drug in patients infected with the novel coronavirus.

AIFA, Italy's drug-regulation agency, said Roche's (RHHBY -1.53%) rheumatoid arthritis drug Actemra didn't help patients with early-stage COVID-19 pneumonia in an Italian clinical trial that it authorized.

An interim look at the first 126 patients enrolled in the study found that the drug didn't reduce severe respiratory symptoms, intensive-care visits, or death, compared to standard of care, so the clinical trial was stopped early.

Many ventilators and respirators lined up for use

Image source: Getty Images.

Actemra, which inhibits interleukin-6, is in the same class of drugs as Sanofi (SNY -0.45%) and Regeneron Pharmaceuticals' (REGN -1.93%) arthritis drug Kevzara, which failed to show an effect in patients with severe cases of COVID-19. Sanofi and Regeneron are continuing to enroll patients who are in critical condition -- meaning they require ventilators, high-flow oxygenation, or treatment in an intensive-care unit.

Interleukin-6 is a cytokine that stimulates the immune system, which, in theory, should help patients fight off the infection. Unfortunately, through a positive-feedback loop, the immune system can hyperreact to the coronavirus that causes COVID-19, resulting in what's called a cytokine storm. The hypothesis is that drugs such as Kevzara or Actemra, which dampen the immune system in rheumatoid arthritis, an autoimmune disease, might help the sickest COVID-19 patients with overactive immune systems that are killing them.

Roche is running a clinical trial of its own, testing Actemra in hospitalized patients with severe COVID-19 pneumonia with data expected this summer. A few weeks ago, the drugmaker also started a clinical trial testing Actemra plus Gilead Sciences' (GILD -1.34%) remdesivir, which received Emergency Use Authorization by the Food and Drug Administration last month.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$41.11 (-1.53%) $0.64
Sanofi Stock Quote
Sanofi
SNY
$38.00 (-0.45%) $0.17
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$63.07 (-1.34%) $0.86
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$691.82 (-1.93%) $-13.60

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.